These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 15928660

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Lack of BRAF mutations in uveal melanoma.
    Rimoldi D, Salvi S, Liénard D, Lejeune FJ, Speiser D, Zografos L, Cerottini JC.
    Cancer Res; 2003 Sep 15; 63(18):5712-5. PubMed ID: 14522889
    [Abstract] [Full Text] [Related]

  • 3. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
    Maat W, Kilic E, Luyten GP, de Klein A, Jager MJ, Gruis NA, Van der Velden PA.
    Invest Ophthalmol Vis Sci; 2008 Jan 15; 49(1):23-7. PubMed ID: 18172070
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea.
    Weber A, Hengge UR, Urbanik D, Markwart A, Mirmohammadsaegh A, Reichel MB, Wittekind C, Wiedemann P, Tannapfel A.
    Lab Invest; 2003 Dec 15; 83(12):1771-6. PubMed ID: 14691295
    [Abstract] [Full Text] [Related]

  • 6. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
    Zuo H, Nakamura Y, Yasuoka H, Zhang P, Nakamura M, Mori I, Miyauchi A, Kakudo K.
    Pathol Int; 2007 Jan 15; 57(1):12-20. PubMed ID: 17199737
    [Abstract] [Full Text] [Related]

  • 7. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2008 Jun 15; 49(6):2348-56. PubMed ID: 18281615
    [Abstract] [Full Text] [Related]

  • 8. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
    Tanami H, Imoto I, Hirasawa A, Yuki Y, Sonoda I, Inoue J, Yasui K, Misawa-Furihata A, Kawakami Y, Inazawa J.
    Oncogene; 2004 Nov 18; 23(54):8796-804. PubMed ID: 15467732
    [Abstract] [Full Text] [Related]

  • 9. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
    Ogawa K, Sun C, Horii A.
    Oncol Rep; 2005 Dec 18; 14(6):1481-5. PubMed ID: 16273242
    [Abstract] [Full Text] [Related]

  • 10. The RAS-BRAF kinase pathway is not involved in uveal melanoma.
    Kiliç E, Brüggenwirth HT, Verbiest MM, Zwarthoff EC, Mooy NM, Luyten GP, de Klein A.
    Melanoma Res; 2004 Jun 18; 14(3):203-5. PubMed ID: 15179189
    [Abstract] [Full Text] [Related]

  • 11. Absence of BRAF and NRAS mutations in uveal melanoma.
    Cruz F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Corless CL.
    Cancer Res; 2003 Sep 15; 63(18):5761-6. PubMed ID: 14522897
    [Abstract] [Full Text] [Related]

  • 12. Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma.
    Alsina J, Gorsk DH, Germino FJ, Shih W, Lu SE, Zhang ZG, Yang JM, Hait WN, Goydos JS.
    Clin Cancer Res; 2003 Dec 15; 9(17):6419-25. PubMed ID: 14695143
    [Abstract] [Full Text] [Related]

  • 13. Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas.
    Pópulo H, Vinagre J, Lopes JM, Soares P.
    Br J Ophthalmol; 2011 May 15; 95(5):715-9. PubMed ID: 20805136
    [Abstract] [Full Text] [Related]

  • 14. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
    Buery RR, Siar CH, Katase N, Gunduz M, Lefeuvre M, Fujii M, Inoue M, Setsu K, Nagatsuka H.
    Oncol Rep; 2011 Oct 15; 26(4):783-7. PubMed ID: 21750866
    [Abstract] [Full Text] [Related]

  • 15. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
    Tsavachidou D, Coleman ML, Athanasiadis G, Li S, Licht JD, Olson MF, Weber BL.
    Cancer Res; 2004 Aug 15; 64(16):5556-9. PubMed ID: 15313890
    [Abstract] [Full Text] [Related]

  • 16. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma.
    Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EA.
    Oncogene; 2006 Jun 29; 25(28):3956-62. PubMed ID: 16474847
    [Abstract] [Full Text] [Related]

  • 17. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
    Yazdi AS, Ghoreschi K, Sander CA, Röcken M.
    Eur J Dermatol; 2010 Jun 29; 20(5):575-9. PubMed ID: 20605766
    [Abstract] [Full Text] [Related]

  • 18. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression.
    Kono M, Dunn IS, Durda PJ, Butera D, Rose LB, Haggerty TJ, Benson EM, Kurnick JT.
    Mol Cancer Res; 2006 Oct 29; 4(10):779-92. PubMed ID: 17050671
    [Abstract] [Full Text] [Related]

  • 19. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
    Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M.
    Cancer Res; 2003 Feb 15; 63(4):756-9. PubMed ID: 12591721
    [Abstract] [Full Text] [Related]

  • 20. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma.
    Lee DA, Cohen JA, Twaddell WS, Palacios G, Gill M, Levit E, Halperin AJ, Mones J, Busam KJ, Silvers DN, Celebi JT.
    Cancer; 2006 Feb 15; 106(4):907-13. PubMed ID: 16421887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.